Lyn regulates creatine uptake in an imatinib-resistant CML cell line.

ABSTRACT:

Background

Imatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl-R) contained elevated Lyn activity and intracellular creatine pools compared to imatinib-sensitive Myl cells.

Methods

Stable isotope metabolic labeling, media creatine depletion, and Na⁺/K⁺-ATPase inhibitor experiments were performed to investigate the origin of creatine pools in Myl-R cells. Inhibition and shRNA knockdown were performed to investigate the specific role of Lyn in regulating the Na⁺/K⁺-ATPase and creatine uptake.

Results

Inhibition of the Na⁺/K⁺

SUBMITTER: Okumu DO 

PROVIDER: S-EPMC7055176 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature